Table 2.
Univariate analysis of impact of each indicator on VAS pain score.
| Statistics | P1 continuous | |
|---|---|---|
| ASA | ||
| II | 309 (93.9%) | 0 |
| III | 20 (6.1%) | 1.5 (0.4, 2.7) 0.010 |
| Height (cm) | 162.0 ± 5.4 | 0.0 (−0.0, 0.1) 0.148 |
| Weight (kg) | 74.7 ± 11.5 | −0.0 (−0.0, 0.0) 0.862 |
| Age (years) | 33.8 ± 4.2 | 0.0 (−0.0, 0.1) 0.424 |
| Preoperative fasting | ||
| No | 143 (43.5%) | 0 |
| Yes | 186 (56.5%) | −0.6 (−1.2, −0.1) 0.029 |
| Hypertension in pregnancy | ||
| Healthy | 304 (92.4%) | 0 |
| With hypertension | 22 (6.7%) | −0.7 (−1.8, 0.5) 0.247 |
| With severe preeclampsia | 3 (0.9%) | 1.5 (−1.4, 4.5) 0.304 |
| Gestational diabetes | ||
| Pregnancy complicated with ketosis | 5 (1.5%) | 0 |
| Gestational diabetes mellitus | 57 (17.3%) | −1.1 (−3.5, 1.2) 0.347 |
| Healthy | 267 (81.2%) | −1.0 (−3.3, 1.3) 0.376 |
| Epidural morphine administration (mg) | ||
| 0 | 125 (38.0%) | 0 |
| 1 | 3 (0.9%) | −0.6 (−3.5, 2.4) 0.709 |
| 1.2 | 3 (0.9%) | −0.9 (−3.8, 2.0) 0.551 |
| 1.5 | 11 (3.3%) | 0.5 (−1.1, 2.1) 0.532 |
| 2 | 187 (56.8%) | −0.8 (−1.4, −0.2) 0.006 |
| Epidural morphine administration (mg) (continuous) | 1.2 ± 1.0 | −0.4 (−0.7, −0.1) 0.008 |
| Different ratios of sufentanil and ropivacaine | ||
| Non-utilization of PCEA | 17 (5.2%) | 0 |
| 75 mg of ropivacaine and no sufentanil (0 μg).” | 1 (0.3%) | −0.5 (−5.7, 4.6) 0.841 |
| 25 μg of sufentanil and no ropivacaine (0 mg). | 11 (3.3%) | 0.3 (−1.6, 2.2) 0.770 |
| 25 μg of sufentanil and 100 mg ropivacaine | 153 (46.5%) | 0.4 (−0.9, 1.6) 0.576 |
| 25 μg of sufentanil and 150 mg ropivacaine | 1 (0.3%) | 0.5 (−4.7, 5.6) 0.858 |
| 25 μg of sufentanil and 50 mg ropivacaine | 7 (2.1%) | −0.7 (−2.9, 1.6) 0.558 |
| 25 μg of sufentanil and 60 mg ropivacaine | 1 (0.3%) | −1.5 (−6.7, 3.6) 0.561 |
| 25 μg of sufentanil and 75 mg ropivacaine | 120 (36.5%) | 0.3 (−1.0, 1.6) 0.629 |
| 25 μg of sufentanil and 80 mg ropivacaine | 1 (0.3%) | 1.5 (−3.7, 6.6) 0.576 |
| 30 μg of sufentanil and 100 mg ropivacaine | 1 (0.3%) | 0.5 (−4.7, 5.6) 0.858 |
| 30 μg of sufentanil and 75 mg ropivacaine | 2 (0.6%) | 2.5 (−1.3, 6.2) 0.197 |
| 30 μg of sufentanil and no ropivacaine (0 mg). | 1 (0.3%) | 0.5 (−4.7, 5.6) 0.858 |
| 35 μg of sufentanil and 100 mg ropivacaine | 1 (0.3%) | −4.5 (−9.7, 0.6) 0.086 |
| 40 μg of sufentanil and 100 mg ropivacaine | 3 (0.9%) | 2.1 (−1.0, 5.3) 0.183 |
| 50 μg of sufentanil and no ropivacaine (0 mg). | 4 (1.2%) | −1.8 (−4.6, 1.0) 0.211 |
| 50 μg of sufentanil and 100 mg ropivacaine | 4 (1.2%) | −2.5 (−5.3, 0.3) 0.076 |
| 50 μg of sufentanil and 50 mg ropivacaine | 1 (0.3%) | −5.5 (−10.7, −0.4) 0.036 |
| Use of PCEA | ||
| No | 17 (5.2%) | 0 |
| Yes | 312 (94.8%) | 0.2 (−1.0, 1.5) 0.698 |
| Intraoperative blood loss (ml) (continuous) | 833.8 ± 182.4 | 0.0 (−0.0, 0.0) 0.090 |
| Intraoperative rehydration (ml) (continuous) | 430.7 ± 124.3 | 0.0 (−0.0, 0.0) 0.392 |